Black Diamond TherapeuticsvsMerck & Company

BDTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

BDTX

Black Diamond Therapeutics, Inc.

$1.47

Value $84M

-3.29%
BDTX's page

MRK

Merck & Company, Inc.

$147.76

Value $365B

+0.55%
MRK's page

Black Diamond Therapeutics (BDTX) has a market value of $84M and Merck & Company (MRK) $365B. Over the last year, with dividends, BDTX moved -69.8% and MRK +66.3%. Dividend yield: BDTX none, MRK 2.30%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BDTX$84M

    MRK$365B

    MRK is 4,338 times BDTX

  • Revenue, 12 months

    BDTX$0

    MRK$67.4B

  • Net income, 12 months

    BDTX-$44M

    MRK$2.5B

  • Operating margin

    BDTX17.9%

    MRK–

  • ROIC

    BDTX-39.8%

    MRK3.9%

    43.7 points apart

  • P/E

    BDTX–

    MRK148.9

  • Dividend yield

    BDTX0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    BDTX-81.0%

    MRK+104.9%

    185.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BDTX-81.0%

MRK+104.9%

10020020222023202420252026
Returns by period
PeriodBDTXWith dividendsMRKWith dividends
1 year since November 12, 2025-69.8%Price -69.8%+66.3%Price +61.6%
3 years since November 13, 2023-22.6%-8.2% a yearPrice -22.6%+58.0%+16.5% a yearPrice +44.2%
5 years since November 12, 2021-81.0%-28.2% a yearPrice -81.0%+104.9%+15.4% a yearPrice +75.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BDTXBlack Diamond TherapeuticsMRKMerck & Company

Valuation

BDTXMRK
Valuation
Price$1.47$147.76
Market value$84M$365B
Enterprise value (EV)–$409B
P/E–148.9
P/E, 5-year median–14.8
P/B1.08.1
EV/EBIT–86.0
Free cash flow yield–4.0%

Results and growth

BDTXMRK
Results and growth
Revenue, 12 months$0$67.4B
Net income, 12 months-$44M$2.5B
Free cash flow, 12 months-$33M$14.7B
Earnings per share, 12 months-$0.76$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

BDTXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin17.9%–
Net margin32.0%3.6%
ROIC-39.8%3.9%
ROE-41.8%5.2%

Balance sheet

BDTXMRK
Balance sheet
Cash$102M$9.7B
Total debt$16M$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

BDTXMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BDTX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Black Diamond Therapeutics or Merck & Company?

By market value, Merck & Company ($365B) is about 4,338.0 times Black Diamond Therapeutics ($84M), at today's prices.

How did BDTX and MRK stock do over the last 5 years?

Since November 12, 2021, BDTX's price moved -81.0% and MRK's +75.9%. With dividends: BDTX -81.0% (-28.2% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, BDTX or MRK?

The dividend yield at today's price is none for Black Diamond Therapeutics and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Black Diamond Therapeutics or Merck & Company?

Over the last twelve months, the net margin was 32.0% for Black Diamond Therapeutics and 3.6% for Merck & Company, and the operating margin 17.9% and –. Revenue was $0 and $67.4B.

Which is the better investment, Black Diamond Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.